New Jersey-based Seqirus announced today that the U.S. Food and Drug Administration (FDA) granted supplemental approval of a multi-dose vial presentation of the AUDENZ™ pandemic influenza vaccine.
AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to help protect individuals six months of age and older against influenza A(H5N1) in the event of a pandemic.
The U.S. FDA initially approved this novel influenza vaccine in February 2020 in a single dose, prefilled syringe presentation.
Read More
